# Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors

> **NCT02966548** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 35 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Relatlimab
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT02966548
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-04
- **Primary completion:** 2024-07-09
- **Final completion:** 2024-07-09
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2025-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02966548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02966548, "Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02966548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*